Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $142 from $135 and keeps an Outperform rating on the shares after hosting key opinion leaders to discuss setmelanotide’s potential in hypothalamic obesity. The leaders expressed optimism that setmelanotide will be effective for all their patients even in those without hypothalamic function, the analyst tells investors in a research note. Citizens thinks setmelanotide’s approval is likely by the December 20 FDA action date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals: Strong Commercial Strategy and Promising Market Potential for aHO Treatment Justifies Buy Rating
- Rhythm Pharmaceuticals price target raised to $122 from $109 at Morgan Stanley
- Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results
- Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide
- Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study